Folate receptor overexpression is associated with poor outcome in breast cancer

被引:191
作者
Hartmann, Lynn C.
Keeney, Gary L.
Lingle, Wilma L.
Christianson, Teresa J. H.
Varghese, Bindu
Hillman, David
Oberg, Ann L.
Low, Philip S.
机构
[1] Mayo Clin, Ctr Canc, Div Med Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Rochester, MN 55905 USA
[3] Mayo Clin, Ctr Canc, Dept Pathol, Rochester, MN 55905 USA
[4] Mayo Clin, Ctr Canc, Div Biostat, Rochester, MN 55905 USA
[5] Purdue Univ, W Lafayette, IN 47907 USA
[6] Purdue Canc Ctr, Dept Chem, W Lafayette, IN USA
关键词
folate receptor; breast cancer; prognosis;
D O I
10.1002/ijc.22811
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The high affinity folate receptor is a membrane-associated glycoprotein that is preferentially expressed in cancers of epithelial origin and rarely expressed in normal cells. We examined its expression pattern in breast cancer, utilizing a tissue microarray containing samples from 63 invasive breast cancers from women with divergent clinical outcomes. Thirty-three women comprised the poor outcome group with a median time to recurrence of 1.9 years. Thirty women, the good outcome group, were free of recurrence for a minimum of 7 years after diagnosis. The intensity of folate receptor staining was strongly correlated with outcome. There were two summary categories of staining intensity: weak (n = 42) or strong (n = 21). In the strong staining group, 17 of 21 women (81%) have recurred and their median survival is 2.4 years. In the weak staining group, 16 of 42 women (38%) have recurred. Their median survival is not estimable. After adjustment for tumor size, nodal status, ER status, adjuvant therapy, histology and tumor grade, strong staining for the folate receptor remained significantly associated with poor outcome, p < 0.001. Our work requires validation in a larger cohort, but supports the possibility of using folate receptor-targeted approaches in the management of breast cancer. (C) 2007 Wiley-Liss, Inc.
引用
收藏
页码:938 / 942
页数:5
相关论文
共 35 条
[1]  
ANTONY AC, 1992, BLOOD, V79, P2807
[2]   A step further in understanding the biology of the folate receptor in ovarian carcinoma [J].
Bagnoli, M ;
Canevari, S ;
Figini, M ;
Mezzanzanica, D ;
Raspagliesi, F ;
Tomassetti, A ;
Miotti, S .
GYNECOLOGIC ONCOLOGY, 2003, 88 (01) :S140-S144
[3]  
BOTTERO F, 1993, CANCER RES, V53, P5791
[4]   In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma [J].
Bruckheimer, E ;
Harvie, P ;
Orthel, J ;
Dutzar, B ;
Furstoss, K ;
Mebel, E ;
Anklesaria, P ;
Paul, R .
CANCER GENE THERAPY, 2004, 11 (02) :128-134
[5]  
CAMPBELL IG, 1991, CANCER RES, V51, P5329
[6]   The vitamin D receptor as a therapeutic target [J].
Campbell, Moray J. ;
Adorini, Luciano .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (05) :735-748
[7]   An application of changepoint methods in studying the effect of age on survival in breast cancer [J].
Contal, C ;
O'Quigley, J .
COMPUTATIONAL STATISTICS & DATA ANALYSIS, 1999, 30 (03) :253-270
[8]  
Evans CO, 2003, CANCER RES, V63, P4218
[9]   Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies [J].
Figini, M ;
Ferri, R ;
Mezzanzanica, D ;
Bagnoli, M ;
Luison, E ;
Miotti, S ;
Canevari, S .
GENE THERAPY, 2003, 10 (12) :1018-1025
[10]  
FRANKLIN WA, 1994, INT J CANCER, P89